Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Tamibarotene (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms SELECT-AML-1
Sponsors Syros Pharmaceuticals

15 Aug 2024 Status changed from recruiting to active, no longer recruiting.
12 Aug 2024 According to a Syros Pharmaceuticals media release, pivotal CR data expected by the middle of the fourth quarter of 2024.
31 Jul 2024 According to a Syros Pharmaceuticals media release,clinical activity and tolerability data from a prespecified analysis of more than 40 patients to be presented at the 12 the Annual Meeting of the Society of Hematologic Oncology (SOHO) meeting in September 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com